Multicenter comparison of azithromycin and amoxicillin/clavulanate in the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease

Current Therapeutic Research

Volumn 56, Issue 10, 1995, Pages 985-995

  Whitlock, Warren ^a  

^a EISENHOWER ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG EFFICACY; DRUG MIXTURE; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0028882359     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0011-393X(95)85105-4     Document Type: Article

References (28)

1. Mortality patterns—United States 1992
2. Epidemiology of COPD: State of the art
3. Advances in the treatment of chronic obstructive pulmonary disease
4. Trends in COPD morbidity and mortality in the United States
5. Acute or chronic respiratory failure: Assessment and management of patients with COPD in the emergent setting
6. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma
7. Treatment of exacerbations of COPD
8. The use of antibiotics in acute bronchitis and acute exacerbations of chronic bronchitis
9. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis
10. Respiratory infections in ambulatory adults: Choosing the best treatment
11. Tissue-directed pharmacokinetics
12. Comparative in vitro activities of new 14- 15- and 16-membered macrolides
13. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms
14. Estimation of azithromycin concentrations in pulmonary tissues and serum after multiple oral doses in normal volunteers
15. Azithromycin versus cefaclor in the treatment of acute exacerbations of chronic obstructive pulmonary disease
16. Newer oral antimicrobials and newer etiologic agents of acute bronchitis and acute exacerbations of chronic bronchitis
17. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
18. Acute bacterial exacerbations in bronchitis and asthma
19. Chronic obstructive pulmonary disease: Current concepts and therapeutic approaches
20. A comparison of doxycycline and cefaclor in acute bacterial exacerbations of chronic bronchial disease
21. Amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections caused by β-lactamase—positive Haemophilus influenzae and Branhamella catarrhalis
22. Clinical toleration and safety of azithromycin in adults and children
23. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters
24. Pharmacokinetic drug interactions of macrolides
25. Lack of effect of azithromycin (AZ) on the pharmacokinetics (PK) of theophylline (T) in man
26. The effect of prescribed daily dose frequency on patient medication compliance
27. Failure of children to receive penicillin by mouth
28. Cost issues and considerations when choosing antimicrobial agents